<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04973358</url>
  </required_header>
  <id_info>
    <org_study_id>35RC21_9796_BUCCOTHERM</org_study_id>
    <secondary_id>2021-A01541-40</secondary_id>
    <nct_id>NCT04973358</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Determine the Effect of a Mouthwash on the Preservation of the Ecology of the Oral Microbiome and Its Compatibility With Health</brief_title>
  <acronym>BUCCOTHERM</acronym>
  <official_title>BUCCOTHERM : Randomized Clinical Trial to Determine the Effect of a Mouthwash on the Preservation of the Ecology of the Oral Microbiome and Its Compatibility With Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The microbiota of the human body is essential to life, and plays an essential role in the&#xD;
      protection and development of various pathological conditions. There is a symbiotic or&#xD;
      mutualistic relationship between humans and their microbiota. However, when the microbiota&#xD;
      becomes dysbiotic, it is associated with pathological conditions. In the oral cavity,&#xD;
      dysbiosis is responsible for caries and periodontal pathologies, but other associations have&#xD;
      been demonstrated or are suspected with distant pathologies (rheumatoid arthritis,&#xD;
      Alzheimer's disease). Mouthwashes are used therapeutically or daily to maintain oral health.&#xD;
      The main studies reporting their effects on the ecology of the oral microbiota are for the&#xD;
      most part limited to Pasteurian culture techniques (40% of bacteria are not yet cultivable).&#xD;
      The advent of new generations of sequencing allows to overcome this limitation and to explore&#xD;
      the complexity of bacterial communities, i.e. the symbiosis or dysbiosis of the entire&#xD;
      bacterial ecosystem. The control of the oral microbiota to prevent pathologies requires a&#xD;
      better knowledge of the oral microbial ecology and will allow the development of new&#xD;
      approaches that consider the process of biofilm formation and the disruption of bacterial&#xD;
      communication networks. The effects of daily mouthwash must therefore be studied at the level&#xD;
      of the entire bacterial community.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Commensal species of the oral microbiota</measure>
    <time_frame>week 14</time_frame>
    <description>Change from baseline in commensal species at 14 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alpha and beta diversity of the oral microbiota</measure>
    <time_frame>week 14</time_frame>
    <description>Change from baseline in alpha and beta diversity at 14 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Coefficient of dysbiosis/symbiosis of the oral microbiota</measure>
    <time_frame>week 14</time_frame>
    <description>Change from baseline in coefficient of dysbiosis/symbiosis at 14 weeks</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Buccal Microbiota</condition>
  <arm_group>
    <arm_group_label>BuccoTherm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>buccotherm mouthwash</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo mouthwash</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>buccotherm mouthwash</intervention_name>
    <description>twice a day for 14 weeks</description>
    <arm_group_label>BuccoTherm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo mouthwash</intervention_name>
    <description>twice a day for 14 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older:&#xD;
&#xD;
          -  with at least 20 permanent natural teeth, excluding crowns;&#xD;
&#xD;
          -  affiliated to a social security system;&#xD;
&#xD;
          -  having received information about the protocol and having given their free, informed&#xD;
             and written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  with periodontitis in the month prior to inclusion;&#xD;
&#xD;
          -  with significant carious lesions deeply modifying the oral microbiota in the month&#xD;
             prior to inclusion;&#xD;
&#xD;
          -  having undergone oral surgical treatment within 3 months prior to inclusion;&#xD;
&#xD;
          -  wearing orthodontic appliances;&#xD;
&#xD;
          -  having undergone periodontal procedures in the month prior to inclusion;&#xD;
&#xD;
          -  suffering from severe chronic pathologies deemed incompatible with study entry;&#xD;
&#xD;
          -  allergic to one of the swab components;&#xD;
&#xD;
          -  allergic to any of the components of the BUCCOTHERM mouthwash or the placebo;&#xD;
&#xD;
          -  on drugs that may cause gingival hypertrophy, such as Hydantoins (phenytoin),&#xD;
             Dihydropyridines, Diltiazem or Ciclosporin;&#xD;
&#xD;
          -  Medications that can cause gingival bleeding (anticoagulants, antiplatelet agents and&#xD;
             aspirin);&#xD;
&#xD;
          -  Antibiotic therapy or professional scaling in the month prior to inclusion;&#xD;
&#xD;
          -  having used oral or topical antibiotics, antiseptics and/or antifungals (e.g.,&#xD;
             mouthwash, dental gels, etc.) in the month prior to inclusion.&#xD;
&#xD;
          -  Subjects with poor written and spoken French language skills;&#xD;
&#xD;
          -  previously included in the BUCCOTHERM study;&#xD;
&#xD;
          -  simultaneously participating in another trial that may interfere with the conduct of&#xD;
             the BUCCOTHERM study or in a period of exclusion after participation in another&#xD;
             clinical study;&#xD;
&#xD;
          -  protected persons (adults under legal protection (legal guardianship, curatorship,&#xD;
             tutorship), persons deprived of liberty, pregnant or breastfeeding women, women of&#xD;
             childbearing age without effective contraception (estrogen-progestin treatments, IUD,&#xD;
             tubal ligation), minors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meuric Vincent</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mevel Nicolas</last_name>
    <phone>02 99 28 25 55</phone>
    <email>dri@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ganivet Anne</last_name>
    <phone>02 99 28 25 55</phone>
    <email>anne.ganivet@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>MEURIC Vincent</last_name>
    </contact>
    <investigator>
      <last_name>BONNAURE-MALLET Martine</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>BOYER Emile</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mouthwash</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

